Table 5.

Treatment-related clinical adverse events in XEC and FEC arms

Adverse Event	XEC (n=61) (%)	FEC (n=70) (%)	P-value*
3/4 grade adverse events	34 (56)	28 (40)	0.072
3/4 grade leukopenia	11 (18)	11 (16)	0.723
3/4 grade nausea, vomiting, and diarrhea	18 (30)	10 (14)	0.034
3/4 grade mucositis	5 (8)	7 (10)	0.721
HFS	35 (57)	8 (11)	0.000
Phlebitis	2 (3)	10 (14)	0.035
Arthralgia and myalgia	3 (5)	6 (8)	0.502
Alopecia	52 (85)	62 (89)	0.572

Note:

^*P-value by chi-square test or Fisher’s exact test when the cell expectation was less than six.

Abbreviations: FEC, 5-FU/epirubicin/cyclophosphamide; 5-FU, 5-fluorouracil; HFS, hand-foot syndrome; XEC, capecitabine/epirubicin/cyclophosphamide.